SLRX:NSD-Salarius Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.4951

Change

0.00 (-0.78)%

Market Cap

USD 2.44M

Volume

4.07K

Analyst Target

USD 4.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.79 (+0.90%)

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

+5.80 (+0.60%)

USD 96.94B
MRNA Moderna Inc

-5.38 (-4.39%)

USD 38.83B
ARGX argenx NV ADR

-7.92 (-2.07%)

USD 23.43B
BNTX BioNTech SE

-0.39 (-0.42%)

USD 22.34B
ALNY Alnylam Pharmaceuticals Inc

-0.90 (-0.59%)

USD 19.15B
GMAB Genmab AS

+0.03 (+0.10%)

USD 18.26B
RPRX Royalty Pharma Plc

+0.12 (+0.43%)

USD 16.73B
BGNE BeiGene Ltd

-7.51 (-4.45%)

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

-0.69 (-0.84%)

USD 15.35B

ETFs Containing SLRX

REM 3.44 % 0.48 %

N/A

N/A
MORT VanEck Mortgage REIT Inco.. 3.09 % 0.42 %

+0.03 (+0%)

USD 0.25B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.83% 32% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.83% 32% F 22% F
Trailing 12 Months  
Capital Gain -72.19% 17% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.19% 17% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -44.41% 7% C- 4% F
Dividend Return -44.41% 7% C- 4% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 80.57% 33% F 19% F
Risk Adjusted Return -55.12% 30% F 19% F
Market Capitalization 2.44M 3% F 2% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.